At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,053 enrolled
Drug / intervention
Risedronate/Cholecalciferol combination +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
For 12months, the Multi Center, Randomized, Open-label, Active Controlled Comparative Clinical Study to Assess the Efficacy and the Safety of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis
In Brief
A Phase 4 clinical trial evaluating Risedronate/Cholecalciferol combination and Risedronate for Osteoporosis. Completed, enrolled 1,053 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy and the safety of Risedronate, cholecalciferol combination tablet in patients with Osteoporosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedAug 2012
Primary CompletionDec 2013
Study CompletionApr 2014
TodayJul 2026
First PostedAug 29, 2012
Enrollment StartJul 4, 2011
Primary CompletionDec 1, 2013
Study CompletionApr 15, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 13.8 years ago
Interventions
Risedronate/Cholecalciferol combinationdrug
Risendronate/Cholecalciferol combination once a week
Risedronatedrug
Risedronate once a week